Clinical Trial: Effectiveness of ABRYSVO(R) Maternal Respiratory Syncytial Virus (RSV) Vaccine Against RSV in Infants in Western Pennsylvania

U.S., Feb. 8 -- ClinicalTrials.gov registry received information related to the study (NCT06813872) titled 'Effectiveness of ABRYSVO(R) Maternal Respiratory Syncytial Virus (RSV) Vaccine Against RSV in Infants in Western Pennsylvania' on Jan. 31.

Brief Summary: Globally, respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract disease (LRTD) in infants. Pfizer has developed ABRYSVO-a bivalent RSV prefusion F protein-based vaccine (RSVpreF) composed of two prefusion F proteins to protect against both RSV-A and RSV-B. In the United States, ABRYSVO has been approved and recommended for active immunization of pregnant individuals from 32 0/7 to 36 6/7 weeks' gestational age for the prevention of LRTD and severe LRTD ca...